Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.
about
Antibody Drug Conjugates: Preclinical ConsiderationsBrief Glutamine Pretreatment Increases Alveolar Macrophage CD163/Heme Oxygenase-1/p38-MAPK Dephosphorylation Pathway and Decreases Capillary Damage but Not Neutrophil Recruitment in IL-1/LPS-Insufflated RatsAnti-CD163-dexamethasone protects against apoptosis after ischemia/reperfusion injuries in the rat liverTargeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug ConjugateAnti-inflammatory liposomes have no impact on liver regeneration in ratsParticipation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells.Equine Arteritis Virus Uses Equine CXCL16 as an Entry ReceptorDexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion.CD163-Macrophages Are Involved in Rhabdomyolysis-Induced Kidney Injury and May Be Detected by MRI with Targeted Gold-Coated Iron Oxide Nanoparticles.Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats.Scavenger Receptor-Mediated Targeted Treatment of Collagen-Induced Arthritis by Dextran Sulfate-Methotrexate Prodrug.Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytesCD163 and inflammation: biological, diagnostic, and therapeutic aspects.Targeted drug delivery to macrophages.Receptor-based targeting of therapeutics.Targeted delivery systems for biological therapies of inflammatory diseases.Receptor-targeted drug delivery: current perspective and challenges.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.Alcoholic hepatitis: The pivotal role of Kupffer cells.Recent advances in nanomedicines for the treatment of rheumatoid arthritis.Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.An immunosuppressive antibody-drug conjugate.Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Effects of delayed delivery of dexamethasone-21-phosphate via subcutaneous microdialysis implants on macrophage activation in rats.Introducing MARCo: Histoserological Findings of a Multi-Organic Paraneoplastic Syndrome in Cutaneous Melanoma Patients.Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.Gene-edited pigs are protected from porcine reproductive and respiratory syndrome virus.Antibody-drug conjugates for non-oncological indications.Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.Anti-inflammatory effects of octadecylamine-functionalized nanodiamond on primary human macrophages.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells.Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes.Biodistribution and PET imaging of a novel [68Ga]-anti-CD163-antibody conjugate in rats with collagen-induced arthritis and in controls.
P2860
Q27022321-61EED93E-8AD0-4BB7-9D76-E5F9F0ACA3DEQ35683525-EE0366EA-DAA2-4E6D-B270-A554D01DCF82Q36146299-B7897E77-060D-429F-8FE3-045DB5088B49Q36296686-9BE00CB0-94A5-49BC-8E18-E9B4B0CA524FQ36387936-4CBA1653-5718-4598-BF8F-DB5488F9C0A9Q36407773-7E547F32-A76D-4989-BD38-33DA6EA7EFB9Q36694094-A9D1938B-754F-4623-A2BA-5A48EF7994C9Q36715955-DF52BB11-4B06-4743-991A-343BEC297393Q36882988-DC38D026-E08E-4E87-9F88-34BC305DE7EFQ37014721-79A3D784-B494-4E91-A7EB-53F11443ACF6Q37541839-7D228DC5-5335-435A-ABA1-6B759E89BCBBQ37714138-0C38EC73-22AF-4FB1-8A7C-5A6DC6DE70CFQ38035395-25299C56-59E9-4056-8ACF-79C64F86C0F3Q38071672-86D44F54-E2DA-4A34-93E5-840534CEDC74Q38084739-5B16C97B-40AA-4800-98F7-8A823C05B518Q38264691-4D3B79C6-53D6-45C5-B003-C6F9279844D6Q38265617-7E59B39F-127E-4409-A6C8-2414BF697DC3Q38453769-744FCCD9-69DE-493A-B01F-1F450EF8E281Q38537751-7EE6D144-D9ED-4D85-B388-14DC85E68A99Q38645785-5F6B6805-35FC-4262-8C0E-65292514D34BQ38669113-D3ECF31E-E722-4955-9065-E71A6A0B242AQ38961842-C014287E-DDD7-42E6-BFF0-49FB2F33D262Q42207099-0098F451-54E7-49B3-8620-770ABDEEC780Q42231930-5785DAF3-91F5-4C2B-AA77-9000CC483D26Q42284206-E417B12A-69DE-4F5F-9B16-D5725065AFB7Q42321353-0F31EE7E-8DE0-4D7E-8B0F-7F4A5A42911AQ42364290-6C3AA8FF-997B-4E1F-9D86-5A2C70B87136Q43096291-0E53FE40-8F27-4959-883D-2465AA1EFD7BQ45339636-1C6FAC4A-F11C-447D-9F07-467B23AC4BD8Q46036446-A089B93F-4A94-43DC-A5AB-50D89CDE64D6Q46120241-32F8AA2C-2B80-436A-8E4E-D095DBD733D9Q47132141-A37396FF-EE22-4E47-9FE6-DE598FE5241BQ47145944-961EDD85-DA0E-4DF1-85FB-2F8CA1EBD27AQ47277628-DDF57B66-2D2E-4A19-807A-3F0C4FF7D490Q48259906-CB1B4C81-26AE-4D89-8360-CBDE12BC1313Q51227992-95D1C58D-2A20-474C-8C16-B49AA62C6833Q51747568-D7711EF9-9392-4074-AF9B-539BB1D91537
P2860
Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@ast
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@en
type
label
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@ast
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@en
prefLabel
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@ast
Targeting the hemoglobin scave ...... tory potency of dexamethasone.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Targeting the hemoglobin scave ...... atory potency of dexamethasone
@en
P2093
Mikkel D Petersen
Pia Svendsen
P2860
P304
P356
10.1038/MT.2012.103
P50
P577
2012-05-29T00:00:00Z